Search

Your search keyword '"Barra, Federica"' showing total 3 results
Start Over Author "Barra, Federica" Publication Type Magazines
3 results on '"Barra, Federica"'

1. GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

Author

Lanini, Simone, Capone, Stefania, Antinori, Andrea, Milleri, Stefano, Nicastri, Emanuele, Camerini, Roberto, Agrati, Chiara, Castilletti, Concetta, Mori, Federica, Sacchi, Alessandra, Matusali, Giulia, Gagliardini, Roberta, Ammendola, Virginia, Cimini, Eleonora, Grazioli, Fabiana, Scorzolini, Laura, Napolitano, Federico, Plazzi, Maria M., Soriani, Marco, De Luca, Aldo, Battella, Simone, Sommella, Andrea, Contino, Alessandra M., Barra, Federica, Gentile, Michela, Raggioli, Angelo, Shi, Yufang, Girardi, Enrico, Maeurer, Markus, Capobianchi, Maria R., Vaia, Francesco, Piacentini, Mauro, Kroemer, Guido, Vitelli, Alessandra, Colloca, Stefano, Folgori, Antonella, and Ippolito, Giuseppe

Abstract

Description

Published
2022
Full Text
View/download PDF

2. Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Author

Capone, Stefania, Raggioli, Angelo, Gentile, Michela, Battella, Simone, Lahm, Armin, Sommella, Andrea, Contino, Alessandra Maria, Urbanowicz, Richard A., Scala, Romina, Barra, Federica, Leuzzi, Adriano, Lilli, Eleonora, Miselli, Giuseppina, Noto, Alessia, Ferraiuolo, Maria, Talotta, Francesco, Tsoleridis, Theocharis, Castilletti, Concetta, Matusali, Giulia, Colavita, Francesca, Lapa, Daniele, Meschi, Silvia, Capobianchi, Maria, Soriani, Marco, Folgori, Antonella, Ball, Jonathan K., Colloca, Stefano, and Vitelli, Alessandra

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by the emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health, and there is an urgent need to develop safe and effective vaccines. Here, we report the generation and the preclinical evaluation of a novel replication-defective gorilla adenovirus-vectored vaccine encoding the pre-fusion stabilized Spike (S) protein of SARS-CoV-2. We show that our vaccine candidate, GRAd-COV2, is highly immunogenic both in mice and macaques, eliciting both functional antibodies that neutralize SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and a robust, T helper (Th)1-dominated cellular response. We show here that the pre-fusion stabilized Spike antigen is superior to the wild type in inducing ACE2-interfering, SARS-CoV-2-neutralizing antibodies. To face the unprecedented need for vaccine manufacturing at a massive scale, different GRAd genome deletions were compared to select the vector backbone showing the highest productivity in stirred tank bioreactors. This preliminary dataset identified GRAd-COV2 as a potential COVID-19 vaccine candidate, supporting the translation of the GRAd-COV2 vaccine in a currently ongoing phase I clinical trial (ClinicalTrials.gov: NCT04528641).

Published
2021
Full Text
View/download PDF

3. MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans

Author

Esposito, Ilaria, Cicconi, Paola, D’Alise, Anna Morena, Brown, Anthony, Esposito, Marialuisa, Swadling, Leo, Holst, Peter Johannes, Bassi, Maria Rosaria, Stornaiuolo, Mariano, Mori, Federica, Vassilev, Ventzislav, Li, Wenqin, Donnison, Timothy, Gentile, Chiara, Turner, Bethany, von Delft, Annette, Del Sorbo, Mariarosaria, Barra, Federica, Contino, Alessandra Maria, Abbate, Adele, Novellino, Ettore, Thomsen, Allan Randrup, Christensen, Jan Pravsgaard, Lahm, Armin, Grazioli, Fabiana, Ammendola, Virginia, Siani, Loredana, Colloca, Stefano, Klenerman, Paul, Nicosia, Alfredo, Dorrell, Lucy, Folgori, Antonella, Capone, Stefania, and Barnes, Eleanor

Abstract

Administration of an MHC class II invariant chain–adjuvanted HCV vaccine in humans leads to enhanced immunogenicity via the proteasome pathway.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results